Hydreight Technologies Inc. Announces Closing of $5.4 Million LIFE Offering

In This Article:

Hydreight Technologies Inc.
Hydreight Technologies Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) ("Hydreight" or the "Company"), a North American, fully integrated, mobile clinical network of nurses, doctors, and pharmacy distribution, is pleased to announce that, further to the news releases of the Company dated February 10, 2025, and February 18, 2025, it has closed its previously announced commercially reasonable “best efforts” private placement with Beacon Securities Limited (the "Agent") acting as the sole agent. The Company issued 3,492,300 units of the Company (each, a "Unit") at a price of $1.55 per Unit for aggregate gross proceeds of $5,413,065 (the “Offering”). The Offering was conducted pursuant to an agency agreement dated February 26, 2025, between the Company and the Agent (the “Agency Agreement”).

Shane Madden, the Chief Executive Officer of the Company, commented that "the Company greatly appreciates the support of the market and is extremely happy to see such strong institutional investor demand in the Offering, which has exceeded managements’ initial expectations. We continue to focus on the Company's growth and profitability."

The terms of the Offering consisted of the sale of up to 2,581,000 Units, subject to an option of the Agent to increase the number of offered Units by up to an additional 3,710,000 Units (the “Agent’s Option”). The Agent’s Option was exercised for a total of 911,300 additional Units. The Units were issued pursuant to the listed issuer financing exemption (the “Listed Issuer Financing Exemption") under Part 5A of National Instrument 45-106 – Prospectus Exemptions ("NI 45-106").

Each Unit consists of one common share in the capital of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant") of the Company. The Warrants were issued pursuant to a warrant indenture dated February 26, 2025, between the Company and Odyssey Trust Company as warrant agent and each Warrant entitles the holder thereof to acquire one common share of the Company (each, a "Warrant Share") at a price of $2.00 per Warrant Share for a period of 36 months from the closing date of the Offering.

As consideration for acting as agent, the Agent received (i) a cash commission of $257,823.90, (ii) a corporate finance fee of $70,297.50, and (iii) 209,538 non-transferable compensation options (the “Compensation Options”), exercisable for a period of 24 months following the Closing Date to acquire, in aggregate, that number of common shares in the capital of the Company (the “Compensation Option Shares”) at an exercise price equal to $1.55 per Compensation Option Share.